NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'
Pioneering a Paradigm Shift in Pain Treatment, Accelerating Global Market Expansion SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product...
NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches
SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food...